GCNT3 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine inhibits GCNT3 by blocking protein kinase C (PKC), an enzyme involved in various cellular processes including signaling pathways that regulate gene expression and protein function. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits GCNT3 by disrupting the activity of Golgi α-mannosidase II, an enzyme critical for protein glycosylation, which ultimately affects the function and expression of GCNT3. | ||||||
Castanospermine | 79831-76-8 | sc-201358 sc-201358A | 100 mg 500 mg | $184.00 $632.00 | 10 | |
Castanospermine inhibits GCNT3 by interfering with the function of α-glucosidase I, an enzyme involved in N-linked glycosylation, which impacts the processing and activity of GCNT3. | ||||||
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside | 3554-93-6 | sc-203427 sc-203427A | 100 mg 1 g | $350.00 $3184.00 | 2 | |
Benzyl α-GalNAc inhibits GCNT3 by competitively binding to the enzyme's active site, preventing the attachment of galactose to glycoproteins and thereby hindering the activity of GCNT3. | ||||||
Kifunensine | 109944-15-2 | sc-201364 sc-201364A sc-201364B sc-201364C | 1 mg 5 mg 10 mg 100 mg | $135.00 $540.00 $1025.00 $6248.00 | 25 | |
Kifunensine inhibits GCNT3 by inhibiting α-mannosidase I, a key enzyme in N-linked glycosylation, leading to abnormal glycosylation patterns that interfere with GCNT3 function. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits GCNT3 by blocking the synthesis of N-linked glycoproteins, disrupting the proper folding and processing of glycoproteins, which indirectly affects the function of GCNT3. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose inhibits GCNT3 by competitively inhibiting glucose uptake, leading to decreased availability of substrates required for glycosylation, which impairs GCNT3 activity. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A inhibits GCNT3 by disrupting protein trafficking from the endoplasmic reticulum (ER) to the Golgi apparatus, interfering with glycosylation processes essential for GCNT3 function. | ||||||
Deoxynojirimycin | 19130-96-2 | sc-201369 sc-201369A | 1 mg 5 mg | $73.00 $145.00 | ||
1-Deoxynojirimycin inhibits GCNT3 by inhibiting α-glucosidase II, an enzyme required for N-linked glycosylation, leading to aberrant glycoprotein processing and impaired GCNT3 function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin inhibits GCNT3 by disrupting calcium homeostasis and inducing ER stress, leading to dysfunction of glycosylation processes that are essential for GCNT3 activity and expression. | ||||||